Chemotherapy in Mesothelioma
Chemotherapy remains a primary treatment option for mesothelioma. This aggressive cancer develops in the lining of the lungs, abdomen, or heart, most often after asbestos exposure. Therefore, doctors frequently use chemotherapy to slow tumour growth and relieve symptoms when surgery is not possible.
Standard chemotherapy for mesothelioma usually combines two drugs. Pemetrexed paired with cisplatin forms the most common first-line regimen. Additionally, some patients receive carboplatin instead of cisplatin if they cannot tolerate the stronger platinum drug. These combinations aim to damage cancer cell DNA and reduce the tumour’s ability to divide. Treatment typically runs in cycles over several months.
Response rates vary among patients. Some experience tumour shrinkage and improved breathing or reduced pain. However, mesothelioma often resists chemotherapy over time. Moreover, side effects such as fatigue, nausea, low blood counts, and kidney strain can limit how long treatment continues. Doctors monitor patients closely and may adjust doses or switch regimens when toxicity becomes high.
Newer approaches seek to improve outcomes. Immunotherapy drugs are now combined with chemotherapy in many cases. Furthermore, researchers are testing targeted agents and maintenance therapies that follow initial chemotherapy. Clinical trials also explore heated chemotherapy delivered directly into the chest or abdomen after surgery. These methods try to increase drug concentration at the tumour site while reducing systemic exposure.
Chemotherapy alone rarely cures mesothelioma. It mainly extends survival and improves quality of life for suitable patients. As a result, treatment plans usually combine chemotherapy with other options when possible. Ongoing research continues to refine drug combinations and identify which patients benefit most from chemotherapy-based approaches.